X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) largest shareholders are individual investors with 52% ownership, institutions own 31% [Yahoo! Finance]
Catalio-Backed Rhapsogen Names Renato Skerlj, Ph.D., Chief Executive Officer [Yahoo! Finance]
X4 Pharmaceuticals (NASDAQ:XFOR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Should You Buy X4 Pharmaceuticals (XFOR) After Golden Cross? [Yahoo! Finance]
X4 Pharmaceuticals (NASDAQ:XFOR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.